PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34284202-0	2021	Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.	selinexor	37-46	KRAS proto-oncogene, GTPase	Homo sapiens	50-54	
35573474-7	2022	KRAS G12C inhibitors in combination with selinexor suppressed the proliferation of KRAS G12C mutant cancer cell lines in a synergistic manner.	selinexor	41-50	KRAS proto-oncogene, GTPase	Homo sapiens	83-87	
35573474-8	2022	Moreover, combined treatment of selinexor with KRAS G12C inhibitors resulted in enhanced spheroid disintegration, reduction in the number and size of colonies formed by G12C mutant cancer cells.	selinexor	32-41	KRAS proto-oncogene, GTPase	Homo sapiens	47-51	
35573474-10	2022	In an in vivo KRAS G12C cell-derived xenograft model, oral administration of a combination of selinexor and sotorasib was demonstrated to reduce tumor burden and enhance survival.	selinexor	94-103	KRAS proto-oncogene, GTPase	Homo sapiens	14-18	
28647672-7	2017	A multicenter phase 1/2 clinical trial of selinexor in previously treated advanced KRAS-mutant NSCLC is under way.	selinexor	42-51	KRAS proto-oncogene, GTPase	Homo sapiens	83-87